Literature DB >> 8474312

Catabolism of low-density lipoprotein is altered in experimental chronic renal failure.

R J Shapiro1.   

Abstract

Catabolism of low-density lipoprotein is altered in experimental chronic renal failure. In patients with chronic renal failure, cardiovascular disease accounts for a significant proportion of all deaths. Several factors contribute to the "accelerated" atherosclerosis in this population, including hyperlipidemia, the pathogenesis of which is multifactorial. We investigated low-density lipoprotein (LDL) metabolism in a remnant model of chronic renal failure in the guinea pig. After one and two-thirds nephrectomy, creatinine clearance decreased to one-sixth normal. Plasma cholesterol and triglyceride (TG) levels increased with induction of renal failure. Analysis of lipoprotein composition disclosed significant TG enrichment of both uremic very-low-density lipoprotein (VLDL) and uremic LDL compared with control lipoproteins. Plasma clearance of homologous LDL was evaluated in turnover studies in control and uremic guinea pigs. To discriminate between differences in catabolism related to the uremic lipoprotein particle and to the uremic host milieu, a crossover protocol was used comparing the fractional catabolic rate (FCR) after simultaneous injection into control and uremic animals of 125I-control LDL and 131I-uremic LDL. The FCR of native LDL was slower in uremic animals than in controls. In addition, FCR of uremic LDL was significantly less than that of control LDL in both groups. Degradation studies in cultured fibroblasts indicated substantially reduced degradation of uremic LDL compared with control LDL. These results suggest dual abnormalities of LDL catabolism in renal failure that are not only related to alterations in clearance mechanisms in the uremic environment, but also suggest important functional differences in the LDL particle itself isolated from uremic animals.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8474312     DOI: 10.1016/0026-0495(93)90030-r

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  5 in total

1.  Immune dysregulation accelerates atherosclerosis and modulates plaque composition in systemic lupus erythematosus.

Authors:  Aleksandar K Stanic; Charles M Stein; Adam C Morgan; Sergio Fazio; MacRae F Linton; Edward K Wakeland; Nancy J Olsen; Amy S Major
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-24       Impact factor: 11.205

Review 2.  Avenues for post-translational protein modification prevention and therapy.

Authors:  Mengyao Tang; Sahir Kalim
Journal:  Mol Aspects Med       Date:  2022-02-25

3.  Lipids, lipoproteins and apolipoproteins abnormalities in patients undergoing dialysis.

Authors:  X Yang; H Wang; Z Zhu; A Deng
Journal:  J Tongji Med Univ       Date:  1997

4.  Protein carbamylation and chronic kidney disease progression in the Chronic Renal Insufficiency Cohort Study.

Authors:  Sahir Kalim; Anders H Berg; Subbian Ananth Karumanchi; Ravi Thadhani; Andrew S Allegretti; Sagar Nigwekar; Sophia Zhao; Anand Srivastava; Dominic Raj; Rajat Deo; Anne Frydrych; Jing Chen; James Sondheimer; Tariq Shafi; Matthew Weir; James P Lash
Journal:  Nephrol Dial Transplant       Date:  2021-12-31       Impact factor: 7.186

Review 5.  Protein carbamylation in kidney disease: pathogenesis and clinical implications.

Authors:  Sahir Kalim; S Ananth Karumanchi; Ravi I Thadhani; Anders H Berg
Journal:  Am J Kidney Dis       Date:  2014-07-16       Impact factor: 8.860

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.